US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard

Saturday
July 02, 2022

Sign In
Subscribe
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
  • Epaper
  • More
    • Subscribe
    • COVID-19
    • Bangladesh
    • Splash
    • Videos
    • Games
    • Long Read
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
SATURDAY, JULY 02, 2022
US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients

Coronavirus chronicle

Reuters
29 May, 2022, 08:40 am
Last modified: 29 May, 2022, 09:04 am

Related News

  • Asia's factories feeble despite China bounce, feeds global recession fears
  • North Korea blames 'alien things' near border with South for Covid outbreak
  • S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Easing Covid-19 rules, growth focus aid China bulls' cautious return
  • 'We did not face an extreme crisis with Omicron. But this wave is spreading faster'

US doctors reconsider Pfizer's Paxlovid for lower-risk Covid patients

Reuters
29 May, 2022, 08:40 am
Last modified: 29 May, 2022, 09:04 am
Photo: Collected
Photo: Collected

 Use of Pfizer Inc's Covid-19 antiviral Paxlovid spiked this week, but some doctors are reconsidering the pills for lower-risk patients after a US public health agency warned that symptoms can recur after people complete a course of the drug, and that they should then isolate a second time.

More quarantine time "is not a crowd-pleaser," Dr Sandra Kemmerly, an infectious disease specialist at Ochsner Health in New Orleans, told Reuters. "For those people who really aren't at risk ... I would recommend that they not take it."

Use of Pfizer's Paxlovid, authorized to treat newly infected, at-risk people in order to prevent severe illness, has soared as infections have risen. More than 162,000 courses were dispensed last week - compared with an average of 33,000 a week since the drug was launched late last year, according to government data. Biden administration officials have pushed for wide use of Paxlovid, which the government purchased and provides free.

But higher use has also come with more reports from people who say their symptoms eased with Paxlovid only to return a few days after finishing a five-day regimen of the pills.

On Tuesday, the Centers for Disease Control and Prevention, citing case reports and concerns that relapsed patients could spread the virus, issued its advisory that Paxlovid users should isolate for a second five days if symptoms rebound.

"I am shying away from giving it to people who are very low- risk, and are not terribly ill, particularly people who are vaccinated and boosted," said Dr Bruce Farber, chief of public health and epidemiology for Northwell Health. He said he is still recommending Paxlovid for people who have significant health conditions or are over age 75.

Pfizer, in an email, said it is monitoring the data, but believes the return of detectable virus is uncommon and not uniquely associated with its drug. "We have not seen any resistance emerge to date in patients treated with Paxlovid," a spokesperson said.

Paxlovid's emergency authorization stipulates that it should be used only for newly infected people with risk factors, but doctors said many others have sought out a prescription.

"We get a lot of requests - maybe somebody is traveling and they want to take it just in case," said Dr Tara Vijayan, infectious disease specialist at UCLA Health in Los Angeles. "We are not offering it as a just-in-case."

The CDC also said it is unclear whether cases of rebound symptoms have anything to do with Paxlovid, or are simply part of the natural trajectory of Covid-19. The agency did not flag any specific concerns about health effects.

"Covid historically has had this sort of stuttering course - people will feel better one day and then feel worse the next day, but I can say we haven't seen these rebound symptoms with other Covid treatments," said Vijayan, referring to therapies such as monoclonal antibodies.

"The patients that do get a rebound, it's usually very mild," said Dr Earl Strum, medical director of employee health at Keck Medicine of USC in Los Angeles.

Some question how much Paxlovid is helping given the high number of people vaccinated or previously infected with Covid-19. The drug was authorized in December after a study in unvaccinated, high-risk Covid patients with conditions like diabetes showed an 88% reduction in hospitalization or death.

At the time, the Delta variant was prevalent, but it has since been displaced by the more transmissible Omicron.

"There's so much more baseline immunity around. There's still a lot of infections, but they're not nearly as severe," Northwell's Farber said.

He estimated the rate of Paxlovid-related Covid rebounds at around 10% - higher than the 3-4% rate cited by Pfizer in its trials of the drug.

Jason Gallagher, an infectious diseases expert at Temple University's School of Pharmacy, said the rebounds do not detract from the drug's utility. "It prevents you from going to the hospital ... if you become symptomatic after you stop taking it, that stinks, but the overall drug was a success," he said.

Top News

Pfizer / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • In rain, heat, filth – they fight against cancer
    In rain, heat, filth – they fight against cancer
  • Tejgaon Industrial Area has become an illegal parking lot for all kinds of vehicles, from buses to trucks to rickshaws. Photo: Mumit M
    Rickshaw garages and truck stands: How Tejgaon Industrial Area turned into a mess
  • TBS Illustration
    Universities may launch online classes again after Eid

MOST VIEWED

  • Former North Korean defectors living in South Korea, release balloons containing one dollar banknotes, radios, CDs and leaflets denouncing the North Korean regime, towards the north near the demilitarized zone which separates the two Koreas in Paju, north of Seoul January 15, 2014. REUTERS/Kim Hong-Ji/File Photo
    North Korea blames 'alien things' near border with South for Covid outbreak
  • People wearing protective face masks commute amid concerns over the new coronavirus disease (COVID-19) in Pyongyang, North Korea March 30, 2020, in this photo released by Kyodo. Picture taken March 30, 2020. Mandatory credit Kyodo/via REUTERS
    S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. Reuters: llustration
    BioNTech, Pfizer to start testing universal vaccine for coronaviruses
  • A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. REUTERS/Dado Ruvic/File Photo
    S Korea approves first domestically developed Covid vaccine
  • Photo: Collected
    US medical experts call for Omicron-specific Covid boosters
  • David E Adler. Sketch: TBS
    Who managed Covid-19 best, and why?

Related News

  • Asia's factories feeble despite China bounce, feeds global recession fears
  • North Korea blames 'alien things' near border with South for Covid outbreak
  • S Korea says leaflets sent by defectors unlikely to be cause of Covid in N Korea
  • Easing Covid-19 rules, growth focus aid China bulls' cautious return
  • 'We did not face an extreme crisis with Omicron. But this wave is spreading faster'

Features

The eye-catching commuter: Suzuki Gixxer SF 155

The eye-catching commuter: Suzuki Gixxer SF 155

54m | Wheels
Photo: Collected

Sapiens – A Graphic History 

22h | Book Review
Black-naped Monarch male  Photo: Enam Ul Haque

Black-naped Monarch: A sovereign who never abandoned the Indian subcontinent

23h | Panorama
The 136-year-old company on its last legs

The 136-year-old company on its last legs

1d | Features

More Videos from TBS

Dhaka University celebrating 102nd founding anniversary today

Dhaka University celebrating 102nd founding anniversary today

22h | Videos
Ctg Int'l Trade Fair returns after a 2-year hiatus without Covid restrictions

Ctg Int'l Trade Fair returns after a 2-year hiatus without Covid restrictions

23h | Videos
Bangladeshis among top 6 nationalities seeking asylum in Europe

Bangladeshis among top 6 nationalities seeking asylum in Europe

23h | Videos
RUET organises Robotronics 2.0

RUET organises Robotronics 2.0

23h | Videos

Most Read

1
Padma Bridge from satellite. Photo: Screengrab
Bangladesh

Padma Bridge from satellite 

2
Meet the man behind 'Azke amar mon balo nei'
Splash

Meet the man behind 'Azke amar mon balo nei'

3
Photo: TBS
Bangladesh

Motorcycles banned on Padma Bridge 

4
Photo: Collected
Economy

Tech startup ShopUp bags $65m in Series B4 funding

5
World Bank to give Bangladesh $18b IDA loans in next five years
Economy

World Bank to give Bangladesh $18b IDA loans in next five years

6
Investor Hiru fined Tk2cr for market manipulation
Stocks

Investor Hiru fined Tk2cr for market manipulation

EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2022
The Business Standard All rights reserved
Technical Partner: RSI Lab
BENEATH THE SURFACE
The Dazzling Fake Flowers: Is there any alternative to artificial flowers while decorating homes, showrooms, offices and business establishments? Fresh flowers are undoubtedly beautiful, but they dry out quickly. Hence, the demand for plastic flowers is rising day by day. Traders said these lifelike silk flowers usually come from China and Thailand. The photo was taken from the 29th International Trade Fair of the Chattogram Chamber on Friday. PHOTO: Mohammad Minhaj Uddin

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net